UNSPSC 51434602: Rentiapril

This classification denotes an ace inhibitor with the molecular formula C13H15NO4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D0TAM1017B, chemically known as 4-thiazolidinecarboxylic acid, 2-(2-hydroxyphenyl)-3-(3-mercapto-1-oxopropyl)-, (2r-cis)- but generally known as rentiapril, which bears US NIH Compound Identifier 71244. European Medicines Agency schedules Rentiapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10277MIG. The term RENTIAPRIL is an International Non-Proprietary Name.

UNSPSC 51434602 Rentiapril, a Commodity code, encompasses emergency and acute-care pharmaceutical products that state and local health agencies and public safety departments procure for immediate clinical use. State and local governments are currently buying specific advanced life support medications—epinephrine, labetalol, adenosine, and diltiazem injections—for use by fire rescue and emergency medical services, as well as generic pharmaceuticals and over-the-counter products through cooperative purchasing arrangements serving multiple state and local facilities. Issuing bodies include municipal fire departments and emergency services (such as the City of Tampa), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance) that aggregate demand across participating state agencies and local jurisdictions. Individual emergency procurements are typically structured as IFBs with firm-price bidding and short delivery windows, while cooperative purchasing agreements consolidate multistate demand through RFPs that establish longer-term contracts with multiple vendors.

Recent activity spans Florida, Texas, and Minnesota through multistate cooperative purchasing. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications (due April 8, 2026; contract value estimated at $40,000.00), with delivery required within ten calendar days of order and a one-year base term plus renewal options. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration, administering the MMCAP cooperative purchasing alliance, issued an RFP (S1070000015802) closing March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026. All solicitations require vendor compliance with cGMP, DSCSA, FDA regulations, OSHA safety data sheet requirements, and minimum shelf-life standards, with medications requiring nine to twelve months' expiration dating from point of delivery. The Tampa solicitation includes a 5 percent bid discount for Small Local Business Enterprise participation, capped at $10,000.